Difference between revisions of "Hürthle cell neoplasm"
Jump to navigation
Jump to search
| (9 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Hürthle cell neoplasm''' is a rare tumour of the [[thyroid gland]] that can have a benign or malignant behaviour. | [[Image:Hurthle cell carcinoma -- very high mag.jpg|thumb|right|300px|Micrograph showing a (metastatic) Hürthle cell carcinoma. [[H&E stain]].]] | ||
'''Hürthle cell neoplasm''' is a rare tumour of the [[thyroid gland]] that can have a benign or malignant behaviour. They are generally considered a subset of [[follicular neoplasm]],<ref name=pmid26530486>{{Cite journal | last1 = Wei | first1 = S. | last2 = LiVolsi | first2 = VA. | last3 = Montone | first3 = KT. | last4 = Morrissette | first4 = JJ. | last5 = Baloch | first5 = ZW. | title = PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma. | journal = Endocr Pathol | volume = 26 | issue = 4 | pages = 365-9 | month = Dec | year = 2015 | doi = 10.1007/s12022-015-9403-6 | PMID = 26530486 }}</ref><ref name=pmid24753500>{{Cite journal | last1 = Ustun | first1 = B. | last2 = Chhieng | first2 = D. | last3 = Van Dyke | first3 = A. | last4 = Carling | first4 = T. | last5 = Holt | first5 = E. | last6 = Udelsman | first6 = R. | last7 = Adeniran | first7 = AJ. | title = Risk stratification in follicular neoplasm: a cytological assessment using the modified Bethesda classification. | journal = Cancer Cytopathol | volume = 122 | issue = 7 | pages = 536-45 | month = Jul | year = 2014 | doi = 10.1002/cncy.21425 | PMID = 24753500 }}</ref> which includes [[follicular thyroid carcinoma]] and [[follicular thyroid adenoma]]. | |||
It may be referred to as ''[[oncocytic neoplasm]]''. | It may be referred to as ''[[oncocytic neoplasm]]''. | ||
'''Hürthle cell carcinoma''' and '''Hürthle cell adenoma''' redirect to here. | '''Hürthle cell carcinoma''' and '''Hürthle cell adenoma''' redirect to here. | ||
==General== | ==General== | ||
*Incidence: uncommon. | *Incidence: uncommon. | ||
| Line 17: | Line 19: | ||
Suggestive for carcinoma:<ref name=pmid9697901/> | Suggestive for carcinoma:<ref name=pmid9697901/> | ||
*Male. | *Male. | ||
*>4 cm | *>4 cm. | ||
**Adenomas usu. <3 cm. | **Adenomas usu. <3 cm. | ||
Definite for carcinoma:<ref name=pmid9697901/> | Definite for carcinoma:<ref name=pmid9697901/> | ||
*Lymphovascular invasion. | *[[Lymphovascular invasion]]. | ||
*Capsular invasion. | *Capsular invasion. | ||
===Gross | ====Risk of malignancy by tumour size==== | ||
Risk of malignancy by size - based on a series of 57 cases:<ref name=pmid9563543>{{Cite journal | last1 = Chen | first1 = H. | last2 = Nicol | first2 = TL. | last3 = Zeiger | first3 = MA. | last4 = Dooley | first4 = WC. | last5 = Ladenson | first5 = PW. | last6 = Cooper | first6 = DS. | last7 = Ringel | first7 = M. | last8 = Parkerson | first8 = S. | last9 = Allo | first9 = M. | title = Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy? | journal = Ann Surg | volume = 227 | issue = 4 | pages = 542-6 | month = Apr | year = 1998 | doi = | PMID = 9563543 }}</ref> | |||
{| class="wikitable sortable" | |||
!Size | |||
!Percentage<br>malignant | |||
|- | |||
| <=1 cm | |||
| 17% | |||
|- | |||
|- | |||
| 1-4 cm | |||
| 23% | |||
|- | |||
| >4 cm | |||
| 65% | |||
|} | |||
==Gross== | |||
*Yellow. | *Yellow. | ||
*Encapsulated. | *Encapsulated. | ||
| Line 42: | Line 61: | ||
*Medullary thyroid carcinoma oncocytic variant. | *Medullary thyroid carcinoma oncocytic variant. | ||
*Others. | *Others. | ||
===Images=== | |||
<gallery> | |||
Image: Hurthle cell carcinoma -- intermed mag.jpg | HCC - intermed. mag. (WC) | |||
Image: Hurthle cell carcinoma -- high mag.jpg | HCC - high mag. (WC) | |||
Image: Hurthle cell carcinoma -- very high mag.jpg | HCC - very high mag. (WC) | |||
Image: Hurthle cell carcinoma - atl -- very high mag.jpg | HCC - very high mag. (WC) | |||
</gallery> | |||
==IHC== | ==IHC== | ||
| Line 55: | Line 82: | ||
*[[Thyroid gland]]. | *[[Thyroid gland]]. | ||
*[[Oncocytoma]]. | *[[Oncocytoma]]. | ||
*[[Follicular neoplasm]]. | |||
==References== | ==References== | ||
Latest revision as of 14:04, 17 February 2016
Micrograph showing a (metastatic) Hürthle cell carcinoma. H&E stain.
Hürthle cell neoplasm is a rare tumour of the thyroid gland that can have a benign or malignant behaviour. They are generally considered a subset of follicular neoplasm,[1][2] which includes follicular thyroid carcinoma and follicular thyroid adenoma.
It may be referred to as oncocytic neoplasm.
Hürthle cell carcinoma and Hürthle cell adenoma redirect to here.
General
- Incidence: uncommon.
- This is a general category - includes:
- Hürthle cell adenoma.
- Hürthle cell carcinoma.
- Some advocate total thyroidectomy for all Hürthle cell neoplasms, as it is difficult to reliably differentiate adenomas and carcinomas.[3]
- It can be understood as a special type of follicular neoplasm (including follicular thyroid adenoma and follicular thyroid carcinoma).[4]
- High stage HCC has a poor prognosis.[5]
Adenoma versus carcinoma
Suggestive for carcinoma:[3]
- Male.
- >4 cm.
- Adenomas usu. <3 cm.
Definite for carcinoma:[3]
- Lymphovascular invasion.
- Capsular invasion.
Risk of malignancy by tumour size
Risk of malignancy by size - based on a series of 57 cases:[6]
| Size | Percentage malignant |
|---|---|
| <=1 cm | 17% |
| 1-4 cm | 23% |
| >4 cm | 65% |
Gross
- Yellow.
- Encapsulated.
Microscopic
Features:[4]
- Oncocytes >= 75% of cells:
- Abundant granular, eosinophilic cytoplasm.
- Round regular nucleus +/- prominent nucleolus.
- +/-Degenerative changes.
Negatives:
- Lack nuclear features of papillary thyroid carcinoma.
- Lack features of medullary thyroid carcinoma.
DDx:[7]
- Papillary thyroid carcinoma oncocytic variant.
- Medullary thyroid carcinoma oncocytic variant.
- Others.
Images
HCC - intermed. mag. (WC)
HCC - high mag. (WC)
HCC - very high mag. (WC)
HCC - very high mag. (WC)
IHC
Features:
- TTF-1 +ve (2 of 6 cases in Bejarno et al.,[8] or 6 of 6 cases in Choi et al.[9]).
- Thyroglobulin (6 of 6 cases[8]).
- CK7 (4 of 6 cases[8]).
- HBME-1 +ve (focal in 4 of 6 cases[9]).
- HCK -ve (6 of 6 cases[9]).
- CK19 +ve (focal in 4 of 6 cases[9]).
See also
References
- ↑ Wei, S.; LiVolsi, VA.; Montone, KT.; Morrissette, JJ.; Baloch, ZW. (Dec 2015). "PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma.". Endocr Pathol 26 (4): 365-9. doi:10.1007/s12022-015-9403-6. PMID 26530486.
- ↑ Ustun, B.; Chhieng, D.; Van Dyke, A.; Carling, T.; Holt, E.; Udelsman, R.; Adeniran, AJ. (Jul 2014). "Risk stratification in follicular neoplasm: a cytological assessment using the modified Bethesda classification.". Cancer Cytopathol 122 (7): 536-45. doi:10.1002/cncy.21425. PMID 24753500.
- ↑ 3.0 3.1 3.2 Wasvary, H.; Czako, P.; Poulik, J.; Lucas, R. (Aug 1998). "Unilateral lobectomy for Hurthle cell adenoma.". Am Surg 64 (8): 729-32; discussion 732-3. PMID 9697901.
- ↑ 4.0 4.1 Thompson, Lester D. R. (2006). Endocrine Pathology: A Volume in Foundations in Diagnostic Pathology Series (1st ed.). Churchill Livingstone. pp. 104. ISBN 978-0443066856.
- ↑ Chindris, AM.; Casler, JD.; Bernet, VJ.; Rivera, M.; Thomas, C.; Kachergus, JM.; Necela, BM.; Hay, ID. et al. (Jan 2015). "Clinical and molecular features of Hürthle cell carcinoma of the thyroid.". J Clin Endocrinol Metab 100 (1): 55-62. doi:10.1210/jc.2014-1634. PMID 25259908.
- ↑ Chen, H.; Nicol, TL.; Zeiger, MA.; Dooley, WC.; Ladenson, PW.; Cooper, DS.; Ringel, M.; Parkerson, S. et al. (Apr 1998). "Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?". Ann Surg 227 (4): 542-6. PMID 9563543.
- ↑ Montone KT, Baloch ZW, LiVolsi VA (August 2008). "The thyroid Hürthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review". Arch. Pathol. Lab. Med. 132 (8): 1241–50. PMID 18684023.
- ↑ 8.0 8.1 8.2 Bejarano, PA.; Nikiforov, YE.; Swenson, ES.; Biddinger, PW. (Sep 2000). "Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms.". Appl Immunohistochem Mol Morphol 8 (3): 189-94. PMID 10981870.
- ↑ 9.0 9.1 9.2 9.3 Choi, YL.; Kim, MK.; Suh, JW.; Han, J.; Kim, JH.; Yang, JH.; Nam, SJ. (Oct 2005). "Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.". J Korean Med Sci 20 (5): 853-9. PMID 16224162.